kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Mouse TNFRSF4 / OX40 / CD134 Protein, Fc Tag, 100µg  

Recombinant Mouse TNFRSF4 / OX40 / CD134 Protein, Fc Tag, 100µg

Recombinant Mouse TNFRSF4 / OX40 / CD134 Protein (Val 20 - Pro 211), produced in human 293 cells, Fc Tag

Recombinant Mouse Protein,TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L

More details


Availability: within 7 days

455,00 €

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5

Recombinant Mouse OX40, Fc Tag (OX0-M5259) is expressed from human 293 cells (HEK293). It contains AA Val 20 - Pro 211 (Accession # NP_035789).
Predicted N-terminus: Val 20

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 47.9 kDa. The protein migrates as 55-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg by the LAL method.

>90% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "Correction to: OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target"
Croft, Esfandiari, Chong et al
Am J Clin Dermatol (2024)
(2) "Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancer"
Comen, Budhu, Elhanati et al
iScience (2024) 27 (2), 108880
(3) "Reprogramming macrophage by targeting VEGF and CD40 potentiates OX40 immunotherapy"
Liu, Ma, Yang et al
Biochem Biophys Res Commun (2024) 698, 149546
Showing 1-3 of 2107 papers.